The use of platelet function testing to guide antithrombotic regimens post-percutaneous coronary intervention in patients requiring therapeutic anticoagulation.
Abstract
Background
Platelet reactivity testing may help tailor antithrombotic regimens after percutaneous coronary intervention (PCI). We sought to describe antithrombotic practices and assess 30-day outcomes in patients treated at an academic cardiac catheterization laboratory who underwent platelet reactivity testing following PCI while concurrently on oral anticoagulation (AC).
Methods
Patients on oral AC who underwent PCI and received platelet reactivity testing at an academic medical center between 1/2012 and 9/2022 were reviewed. Patients were grouped by high on-treatment platelet reactivity (PRU ≥208) and a low on-treatment platelet reactivity (PRU <208) status and then analyzed based on whether they were continued on dual antiplatelet therapy (DAPT) or de-escalated to single antiplatelet therapy (SAPT). Rates of major bleeding and stent thrombosis up to 30 days post-PCI were compared using univariate and multivariate analyses.
Results
156 patients were included (mean age 74, 72% male). Post-PCI, platelet reactivity testing revealed adequate platelet inhibition (PRU < 208) in 120 patients (77%) and inadequate inhibition (PRU≥208) in 36 patients (23%). In the group with adequate inhibition, 78 patients (65%) were de-escalated to SAPT. Compared to individuals with adequate inhibition that were continued on DAPT, patients in the SAPT group had a lower rate of major bleeding 30 days post-PCI (1.3% vs. 9.5%, p = 0.05) and with no increase in stent thrombosis rates. In the group with inadequate inhibition, 53% of patients were de-escalated to SAPT, most often with an alternative P2Y12 inhibitor. Compared to individuals with inadequate inhibition that were continued on DAPT, these patients had lower rates of major bleeding at 30 days (0% vs. 12%, p = 0.23) and similar rates of stent thrombosis.
Discussion
In this analysis of a high bleeding and ischemic risk cohort of patients on concurrent AC undergoing PCI at a high-volume academic medical center, patients managed with SAPT post-PCI experienced lower rates of bleeding without a clear increase in ischemic events compared to those continued on DAPT. Antiplatelet de-escalation was left to the treating physician's discretion, and larger prospective studies are needed to corroborate the safety and utility of this strategy in clinical practice.